Perjeta (Pertuzumab) Injection - 420mg Single-Use Vial for Intravenous Infusion

Perjeta (Pertuzumab) Injection - 420mg Single-Use Vial for Intravenous Infusion

<< >>
Usage conditions apply
Downloads
Description (Brief)
(From box) Dilute prior to use; for intravenous infusion only; single-use vial; discard unused portion
(From insert)
PERJETA is a HER2/neu receptor antagonist indicated in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Location
Currently not on view
Object Name
pharmaceutical
biological
date made
ca 2013
product expiration date
2014-02
maker
Genentech, Inc.
place made
United States: California, South San Francisco
Physical Description
plastic (overall material)
glass (overall material)
metal (overall material)
cardboard (overall material)
pertuzumab, 420mg/14 mL (overall ingredient)
Measurements
overall: 1 3/4 in x 2 3/4 in x 3 1/8 in; 4.445 cm x 6.985 cm x 7.9375 cm
overall: 3 in x 2 1/8 in x 2 1/8 in; 7.62 cm x 5.3975 cm x 5.3975 cm
ID Number
2013.0069.09
catalog number
2013.0069.09
accession number
2013.0069
Credit Line
Gift of Genentech, Inc.
subject
Women's Health
See more items in
Medicine and Science: Medicine
Health & Medicine
The Antibody Initiative
Antibody Initiative: Monoclonal Antibodies
Data Source
National Museum of American History
Nominate this object for photography.   

Our collection database is a work in progress. We may update this record based on further research and review. Learn more about our approach to sharing our collection online.

If you would like to know how you can use content on this page, see the Smithsonian's Terms of Use. If you need to request an image for publication or other use, please visit Rights and Reproductions.

Note: Comment submission is temporarily unavailable while we make improvements to the site. We apologize for the interruption. If you have a question relating to the museum's collections, please first check our Collections FAQ. If you require a personal response, please use our Contact page.